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Abstract
Introduction: Cis-acting regulatory single nucleotide polymorphisms (SNPs) at specific loci may modulate
penetrance of germline mutations at the same loci by introducing different levels of expression of the wild-type
allele. We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the
known variable penetrance of BRCA2 mutations might be associated with this mechanism.
Methods: We combined haplotype analysis and differential allelic expression of BRCA2 in breast tissue to identify
expression haplotypes and candidate cis-regulatory variants. These candidate variants underwent selection based
on in silico predictions for regulatory potential and disruption of transcription factor binding, and were functionally
analyzed in vitro and in vivo in normal and breast cancer cell lines. SNPs tagging the expression haplotypes were
correlated with the total expression of several genes in breast tissue measured by Taqman and microarray
technologies. The effect of the expression haplotypes on breast cancer risk in BRCA2 mutation carriers was
investigated in 2,754 carriers.
Results: We identified common haplotypes associated with differences in the levels of BRCA2 expression in human
breast cells. We characterized three cis-regulatory SNPs located at the promoter and two intronic regulatory
elements which affect the binding of the transcription factors C/EBPa, HMGA1, D-binding protein (DBP) and ZF5.
We showed that the expression haplotypes also correlated with changes in the expression of other genes in
normal breast. Furthermore, there was suggestive evidence that the minor allele of SNP rs4942440, which is
associated with higher BRCA2 expression, is also associated with a reduced risk of breast cancer (per-allele hazard
ratio (HR) = 0.85, 95% confidence interval (CI) = 0.72 to 1.00, P-trend = 0.048).
Conclusions: Our work provides further insights into the role of cis-regulatory variation in the penetrance of
disease-causing mutations. We identified small-effect genetic variants associated with allelic expression differences
in BRCA2 which could possibly affect the risk in mutation carriers through altering expression levels of the wild-
type allele.
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Introduction
Unequal expression of the alleles of autosomal genes is
common in the human genome [1,2]. This differential
allelic expression (DAE) is thought to play a major role
in intra-species phenotypic variation as well as indivi-
dual susceptibility to complex diseases. Previous reports
have suggested a role for DAE in cancer, including that
of the colon [3,4], the pancreas [5], the ovary [6] and
the breast [7,8]. Additionally, several cancer risk-asso-
ciated SNPs identified through genome-wide association
studies (GWAS) have been shown to have a role in gene
expression regulation [9-13]. We previously reported
that BRCA2 displays DAE in breast and blood samples
from healthy individuals [14]. Using a coding single
nucleotide polymorphism (SNP) in exon 9 of BRCA2,
rs144848, as a marker for quantifying allelic transcripts
in heterozygous individuals, we observed differences
between alleles as large as four-fold. Additionally, our
data suggested that the cis-regulatory variation responsi-
ble for DAE is in the same haplotype block as rs144848.
Deleterious germline mutations in BRCA2 are rare but
confer a high risk of breast cancer. However, penetrance
estimates vary and several lines of evidence indicate that
other genetic and environmental factors modify the can-
cer risks conferred by these mutations [15-17]. Studies
by the Consortium of Investigators of Modifiers of
BRCA1/2 (CIMBA) have demonstrated that common
alleles in RAD51, FGFR2, MAP3K1, TOX3/TNRC9,
LSP1, SLC4A7/NEK10, a 2q35 locus and a 5p12 locus
affect breast cancer risk in BRCA2 mutation carriers
[18-20]. These loci account for approximately 4% of the
genetic variation observed in the penetrance of BRCA2
mutations in breast cancer.
Most of the deleterious germline mutations in BRCA2
introduce premature termination codons and trigger
nonsense-mediated mRNA decay [11]. Haploinsuffi-
ciency in BRCA2+/- cells has been shown to affect DNA
damage repair of breaks induced by g-irradiation and
mitomycin C [21] which can contribute to cancer pre-
disposition in mutation carrier families. Recently, it was
also reported that primary breast epithelial cells cultured
from BRCA2 mutation carriers and controls have differ-
ences in gene expression signatures [22].
In this study, we set out to identify and characterize cis-
regulatory variation responsible for DAE in BRCA2 and to
determine whether the penetrance of BRCA2 mutations
could be modified by the variable level of expression of
the remaining wild-type allele in heterozygous mutation
carriers. We identified common haplotypes that associate
with different levels of BRCA2 expression and found three
SNPs that alter the binding affinity of transcription factors
and overlap cis-regulatory elements. The expression haplo-
types were also found to correlate with altered expression
in breast tissue of genes whose expression has previously
been reported to be altered in the presence of inherited
BRCA2 mutations. We found one haplotype that was asso-
ciated with higher expression of BRCA2, for which there is
suggestive evidence that it is also associated with a protec-
tive effect for the development of breast cancer in BRCA2
mutation carriers.
Materials and methods
SNP and haplotype analysis
Hapmap release 16 and data from the 1,000 Genomes
Project were accessed [23-26]. Haplotype structure and
linkage disequilibrium analysis were performed using
Haploview software [27,28].
Human tissue samples
B cells and normal breast tissue from healthy individuals
and normal matched breast tissue from cancer patients
were obtained from the Blood Centre and the Tissue
Bank at Addenbrooke’s Hospital as previously described
[14], with approval from the Addenbrooke’s Hospital
Local Research Ethics Committee (REC reference 04/
Q0108/21, 06/Q0108/221 and 07/H0308/161, respec-
tively). The B cell and control normal breast tissue
material was used for the functional analysis and the
DAE study. The normal matched breast tissue was used
for total gene expression studies.
Nucleic acid extraction and processing
DNA was extracted using a conventional SDS/proteinase
K/phenol method. Total RNA was extracted from all
samples using Qiazol (QIAGEN, Crawley, UK) following
the manufacturer’s instructions. The RNA was subse-
quently treated with DNaseI and repurified using acidic
phenol-chloroform, and ethanol precipitation. DNA and
RNA integrity were checked using the Agilent Bioanaly-
zer (Agilent Technologies, Santa Clara, CA, USA).
cDNA was prepared from total RNA with the Super-
Script® III First Strand SuperMix (Invitrogen, Carlsbad,
CA, USA) using random hexamers and oligo-dT pri-
mers, according to the manufacturer’s instructions.
Breast cell lines culture
Breast cancer (PMC42, MCF-7 and SUM-159) and nor-
mal breast (MCF-10A) cell lines were cultured as pre-
viously described [29-32] for extracting nuclear protein
for electrophoretic mobility shift assays and for extract-
ing chromatin for immunoprecipitation assays.
Genotyping of normal blood and breast tissue from
healthy individuals
Genotyping for rs144848 was performed using a fluores-
cent 5’ exonuclease TaqMan assay and the ABI PRISM
Maia et al. Breast Cancer Research 2012, 14:R63
http://breast-cancer-research.com/content/14/2/R63
Page 2 of 15
7900 Sequence Detection Sequence (Applied Biosystems,
Foster City, CA, USA). Genotyping for another six SNPs
that tag common haplotypes for the DAE region in
BRCA2 was carried out by PCR amplification of 150 bp
to 250 bp around the SNP of interest. Primer sequences
are provided in the Supplementary Material (Additional
file 1 Table S1). Products were verified by agarose gel
electrophoresis and sequenced using ABI Big Dye chem-
istry and capillary electrophoresis on an ABI 3730
sequencer (Applied Biosystems).
Affymetrix Genotyping
Thirty-seven normal breast tissue samples were geno-
typed using Affymetrix Genome-Wide SNP 6.0 arrays
(Affymetrix, Santa Clara, CA, USA), following the stan-
dard Affymetrix protocol using 0.5 μg DNA, at AROS
Applied Biotechnology (Aarhus, Denmark). Affymetrix
SNP 6.0 arrays data were pre-processed and analyzed
using the crlmm Bioconductor package [33] implemen-
ted in the R statistical programming language [34]
(GEO: GSE32259).
Quantification of differential allelic gene expression
Differential allelic expression assays were performed as
previously described [14]. Validation was performed by
Sanger sequencing. In brief, replicate PCRs were per-
formed amplifying 100 bp to 200 bp around the coding
SNP of interest; products were verified by agarose gel
electrophoresis and sequenced using ABI Big Dye
chemistry and capillary electrophoresis on an ABI
3730 sequencer (Applied Biosystems). Allelic expres-
sion ratios in cDNA samples were normalized against
the genomic DNA ratios. Primer sequences are pro-
vided as Supplementary Material (Additional file 1
Table S1).
In silico prediction of transcription factor binding
TRANSFAC professional database [35] (Biobase, Ger-
many) ver.2009.4 with vertebrate non redundant
matrices, and MATCH algorithm with core match and
matrix match set to minimize the sum of both false
positives and negative motif matches were used to iden-
tify putative transcription factor binding sites.
Electrophoretic mobility shift assay (EMSA)
EMSA were performed as previously described [9]. Each
EMSA was repeated two or more times for all combina-
tions of cell extract and oligonucleotide, which were
also tested in serial diluting amounts. Oligonucleotide
sequences are provided as Supplementary Material
(Additional file 1 Table S1). Antibodies used for super-
shift competition assays are listed in the Chromatin
Immunoprecipitation section.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed using chromatin
extracted from SUM-159 (cancer), PMC42 (cancer),
MCF-7 (cancer) and MCF10-A (normal) breast cell lines
with antibodies against RNA polymerase II (Abcam,
Cambridge, UK, ab5408-100), H3K79me2 (Abcam,
ab3594), HMGA1a/HMGA1b (Abcam, ab4078), DABP
(Insight Biotechnology Ltd, Wembley, UK, sc-98411-X),
ZFP161 (Abcam, ab68116), C/EBPa (Insight Biotechnol-
ogy Ltd, sc-9314-X), IgG-Rabbit (Insight Biotechnology
Ltd, sc-2027) and IgG Mouse (Insight Biotechnology
Ltd, sc-2025) as recently described [36]. The immuno-
precipitated material was purified using QIAquick PCR
Cleaning kit (Qiagen) and analyzed by PCR for the
regions of interest. Primer sequences are supplied in the
Supplementary Material (Additional file 1 Table S1).
Gene Expression Analysis
The relative gene expression of BRCA2, SPP1, MUC16,
PAX8, BIRC5 and RRM2 was analyzed using Fluidigm
96.96 Dynamic Arrays (Fluidigm, San Francisco, CA,
USA), according to the manufacturer’s instructions, in a
set of normal breast tissue from healthy donors (n =
58). Four housekeeping genes (Actinb, HPRT1, 18S and
GAPDH) were included in the experiments for normali-
zation purposes.
In short, 1.25 μL of cDNA was pre-amplified in a 5 μL
reaction for the specific targets (0.2x of each assay), for
eight cycles. Pre-amplified samples were diluted 1:5
before being utilized. Chips were run on the BioMark™
Real-Time PCR System (Fluidigm). The cycling program
used consisted of 10 minutes at 95°C followed by 40
cycles of 95°C for 15 seconds and one minute at 60°C.
Data were analyzed using the BioMark Gene Expression
Data Analysis software to obtain Ct values. Each chip
(experiment) was run with all assays plated in triplicate
and 94 test samples plus two no-template control sam-
ples. Analysis was performed using the ∆∆Ct method
and normalization was done using the average Ct value
for the two housekeeping genes (Actinb and HPRT1)
that had the most similar distribution of Ct values
across arrays.
Additionally, we analyzed separately 33 normal breast
tissue samples from healthy individuals and 200 normal
breast tissue samples from cancer patients (normal-
matched) without BRCA2 germline mutations, using
Illumina HT12 v3 expression arrays (Illumina, San
Diego, CA, USA) (GEO: GSE32259 and EGA:
EGAS00000000082). Briefly, for each sample set the
bead array package [37] was employed to pre-process
and summarize each Illumina H12 v3 BeadChip follow-
ing quality assessment and the adjustment of spatial
artefacts with the BASH tool [38]. Potential outlier
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arrays were removed by considering the bead-level qual-
ity assurance (QA) scores derived using the control
probes on each array and the remaining samples were
quantile normalized.
Gene expression statistical analysis
All statistical analysis was performed using R version
2.10.1 [34], unless otherwise stated. Differential allelic
expression data were analyzed as previously described
[14]. Comparison of proportions between groups for
haplotype correlation with DAE was tested using the
Chi-square test. The non-parametric Wilcoxon rank
sum test was used for the analysis of BRCA2 expression
versus haplotype. Specific SNP genotype-gene expression
correlations were determined using analysis of variance
(ANOVA) testing for the first type of correlation and
the Student’s t test for the second.
Associations with breast cancer risk for BRCA2 mutation
carriers
Associations with breast cancer risk were evaluated
using women with BRCA2 mutations from 11 studies
from the CIMBA consortium for the seven SNPs defin-
ing the gene expression associated haplotypes. Subjects
participated in clinical or research studies at the host
institutions under ethically approved protocols and writ-
ten informed consent was obtained (Additional file 2
Table S2).
Studies included per SNP in our analysis are shown in
Additional file 3 (Table S3). Sample eligibility and avail-
able information were reported in detail previously and
are provided in Additional file 4[39]. The DNA samples
of ten studies were genotyped by iPLEX Mass Array
platform (Sequenom Inc., Newton, MA, USA) at
Queensland Institute of Medical Research, with a further
study, GEMO, genotyped elsewhere by Taqman assay,
using Applied Biosystems reagents (Applied Biosystems),
for the same seven SNPs. Further details on the geno-
typing and quality control are described in Additional
file 4.
Details of the statistical analysis methods for evaluat-
ing the associations between SNP genotypes and breast
cancer risk have been published previously and are pro-
vided in Additional file 4[18]. In short, we tested the fre-
quency of each SNP in affected (cases) and unaffected
(control) BRCA2 germline mutation carriers. The effect
of each SNP was modelled either as a per-allele HR
(multiplicative model) or as separate HRs for heterozy-
gotes and homozygotes, and these were estimated on
the log scale. Analyses were carried out with the pedi-
gree-analysis software MENDEL [40]. Heterogeneity
between studies was tested by comparing the models
that allowed for study-specific log-HRs against models
in which the same log-HR was assumed to apply to all
studies.
Disease associations for the five common expression
haplotypes were also explored using the software HAP-
STAT [41], under a standard cohort analysis model and
using the low expression haplotype 2 as the reference. It
should be noted that this analysis does not account for
the sampling design and familial relationships of the
participating studies.
Results
Haplotype correlation with levels of expression
Recently, we reported differential allelic expression of
BRCA2 in both normal breast and blood tissue samples
from control individuals [14]. Using the coding SNP
rs144848 for allelic transcript quantification and an alle-
lic expression ratio threshold of 1.2 (log2 = 0.263), we
found that in 45 heterozygous samples tested 29 (64%)
significantly expressed more of the G allele. All hetero-
zygotes showing DAE preferentially expressed the same
allele, indicating that the coding SNP rs144848 is in
linkage disequilibrium (LD) with the regulatory variant
(s). Linkage disequilibrium is however not complete
between the coding and the regulatory SNP(s) as sug-
gested by the fraction of heterozygotes that did not
show DAE, who are likely homozygous for the regula-
tory variant(s).
In this study, for the identification of possible cis-reg-
ulatory polymorphisms we first analyzed the region sur-
rounding BRCA2, which shows very complex linkage
disequilibrium. Using data from HapMap (Data release
24/phase II, dbSNP build 126) and the Haploview soft-
ware, we identified three main haplotype blocks with
two further regions without clear block structure, corre-
sponding to five common haplotypes in the European
population (CEU samples in HapMap) (tag SNPs for the
haplotypes are shown in Table 1). The G allele of the
coding SNP rs144848 tags one of these haplotypes, hap-
lotype 1. As the samples used for the DAE study are all
heterozygous for rs144848, all samples carry haplotype
1. To evaluate the association between the other haplo-
types and the observed DAE we determined the second
haplotype in 41 samples heterozygous for rs144848 used
in the DAE study. For this we genotyped the samples
for the six tag SNPs defining haplotypes 2/3/4/5 and
correlated them with the presence or absence of DAE
(’DAE’ versus ‘no DAE’ in Table 1). All samples carrying
haplotype 2 showed DAE (Sign Test P-value = 0.031)
and samples with haplotype 5 showed a non-significant
predominance in the DAE group. Haplotypes 3 and 4
were found in equal frequency in individuals with and
without DAE. Correlation of DAE ratios versus haplo-
type shows (Figure 1) that haplotypes 2 and 5 have, on
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average, a larger difference in the allelic expression than
haplotypes 3 and 4, meaning that the T allele of
rs144848 is less expressed than the G allele when it is
inherited as haplotype 2 or 5. In view of these results
we defined haplotypes 2 and 5 as ‘lower expression’ and
haplotypes 1, 3 and 4 as ‘higher expression’ haplotypes.
Gene expression profile of breast tissue is dependent on
haplotype
Having identified different expression haplotypes for
BRCA2 we investigated whether these had an effect on
the expression of the eleven genes reported to be altered
by Bellacosa and colleagues [22] in BRCA2 mutation
carriers. We measured the expression level of IGFBP5,
SPP1, RRM2, BIRC5, MUC16 and PAX8 by quantitative
real-time PCR and of all eleven genes using Illumina
HT12 v3 expression microarrays in the normal breast
tissue of healthy controls, in the normal breast tissue of
breast cancer patients (non-carriers of BRCA2 germline
mutations) and also in blood from healthy controls. We
analyzed the results in two ways. The first consisted of
correlating gene expression versus genotype at specific
SNPs that tag different haplotypes, using a linear regres-
sion model and ANOVA analysis. In this analysis the
heterozygous and the common homozygous groups con-
sist of a mixture of high and low expression haplotypes.
To reduce this noise in the data, in the second type of
analysis we assigned samples to three groups: individuals
carrying two high expression haplotypes, individuals car-
rying one high and one low expression haplotype, and
individuals carrying two low expression haplotypes. We
performed Student’s t test analysis for the expression of
each gene between each two groups. This approach
implied a reduction in the number of informative sam-
ples. We found evidence of correlation between four out
of eleven genes (SPP1, PAX8, MUC16 and IGFBP5) and
the expression haplotypes (Figure 2) which we describe
in detail below.
In normal breast tissue from healthy individuals,
higher expression of SPP1 was found in cells homozy-
gous for the rare allele of rs206081, an SNP in strong
LD with the tag for the high-expression haplotype 3 (P-
value = 0.039, Figure 2A). This correlation was in con-
cordance with the expression haplotype analysis in
blood of healthy individuals using real-time PCR data, in
which expression of SPP1 was found to be significantly
higher in individuals carrying two high expression hap-
lotypes (P-value = 0.006, difference expression = 1.74,
Figure 2B), when compared with individuals carrying
one high and one low expression haplotype (no indivi-
duals were identified with two low expression haplo-
types in these samples). This correlation was found to
be in the opposite direction in the normal tissue of
breast cancer patients, with lower SPP1 expression asso-
ciated with a low BRCA2 expression haplotype (P-value
= 0.038, Figure 2A). The gene PAX8 showed a concor-
dant correlation in normal breast from healthy controls
and cancer patients, showing upregulation in rare
homozygous samples for SNPs that correspond to
Table 1 Haplotype frequencies in BRCA2, tag SNPs and DAE distribution
HAPLOTYPE
PATTERN
Freq (%) HapMap
CEU
rs1799943 rs11571579 rs9534174 rs206070 rs144848 rs4942440 rs9567576 DAE No
DAE
hap1 27.5 G T A C G G T 29 12
hap2 24.2 A C G C T G G 10* 0*
hap3 18.8 G T A T T G T 4 4
hap4 11.7 G T G C T A T 10 7
hap5 5 G C G C T G G 5 1
* P-value = 0.031, Sign-Test. CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; DAE, differential allelic expression; SNP,
single nucleotide polymorphism.
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Figure 1 Differential allelic expression association with BRCA2
haplotypes in blood and breast. Fold difference between the G
and the T allele for samples heterozygous for rs144848. ‘Low-
Expression Haplotypes’ are significantly associated with differential
allelic expression and correspond to haplotypes 2 and 5, and ‘High-
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expression and correspond to haplotypes 3 and 4.
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Figure 2 Differential gene expression analysis in normal breast tissue (controls and breast cancer patients) and normal blood samples.
Box plots displaying differentially expressed genes in normal breast samples from healthy controls (n = 29), matched normal breast tissue from
breast cancer patients (n = 144) and blood samples from healthy individuals (n = 20) analyzed by Illumina HT12 v3 arrays and real-time PCR. (A)
Gene expression versus genotype correlations between the genes SPP1, PAX8, MUC16 and IGFBP5 and two SNPs associated with higher
expression of BRCA2, rs206081 (haplotype 3) and rs4942448 (haplotype 4), and one SNP associated with lower expression of BRCA2, rs9567578
(haplotype 2); P-values correspond to ANOVA testing. (B) Gene expression versus expression haplotype correlations for the genes MUC16 and
SPP1; P-values correspond to a two-sided Student’s t-Test. ANOVA, analysis of variance; PCR, polymerase chain reaction; SNP, single nucleotide
polymorphism.
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haplotypes 3 (rs206081) and 4 (rs4942448), both asso-
ciated with higher expression of BRCA2 (P-value =
0.009 in healthy individuals, P-value = 0.018 in cancer
patients; Figure 2A). The expression of MUC16 in the
normal tissue of patients was negatively correlated with
the A allele of rs4942448 (haplotype 4) (P-value = 0.05
in Figure 2A). The upregulation of MUC16 in indivi-
duals carrying two low-expression haplotypes was con-
firmed with the second analysis method (P-values =
0.004 in Figure 2B). The difference in expression
between the high-expression and low-expression haplo-
type groups was -0.125 for the two probes. In the nor-
mal tissue of patients, the expression of IGFBP5 was
significantly lower in samples homozygous for
rs4942448 (haplotype 4), which is associated with lower
BRCA2 expression (P-values = 0.014, Figure 2A).
These results suggest that even small differences in
the expression level of BRCA2, as those associated with
the different haplotypes that we identified, can have an
impact on the gene expression profile of normal breast
tissue in individuals carrying two copies of BRCA2.
Associations with breast cancer risk for BRCA2 mutation
carriers
The seven SNPs that characterize the five expression
haplotypes identified in the DAE study were genotyped
in 2,754 BRCA2 mutation carriers from 11 centers from
the CIMBA consortium (Additional file 3 Table S3,
Additional file 5 Table S4). In total, 1,617 carriers were
censored at a first breast cancer diagnosis and 1,137
were treated as unaffected in the analysis. One SNP dis-
played a significant association with breast cancer in
carriers of BRCA2 mutations (Table 2) at the 5% signifi-
cance level. The minor allele of SNP rs4942440, tagging
the high expression haplotype 4, was associated with a
reduced breast cancer risk (per-allele HR = 0.85, 95% C.
I. = 0.72 to 1.00, P-trend = 0.048). There was no evi-
dence of heterogeneity in the HRs across studies (P-het-
erogeneity = 0.20, Additional file 6 Figure S1). No
associations were observed with the other SNPs (Addi-
tional file 5 Table S4). Similar to the gene expression
analysis presented above, the association analysis based
on each SNP in isolation does not describe the effects of
each haplotype separately, as there is no distinction
between low and high expression haplotypes in the het-
erozygous and common homozygous groups.
To address this fact we performed a haplotype analysis
using standard cohort analysis in which the low-expres-
sion haplotypes 2 and 5 were considered as reference.
This revealed that each copy of the higher-expression
haplotype 4 was associated with a reduced risk of breast
cancer for BRCA2 mutation carriers (HR = 0.84, 95%CI:
0.73 to 0.97, P = 0.014) (Additional file 7 Table S5).
However, this analysis does not take into account the
non-random sampling of mutation carriers with respect
to disease phenotype, or possible family relations within
the individuals studied, so inference based on this analy-
sis is not directly comparable with the single SNP analy-
sis which was based on modelling the retrospective
likelihood. Nevertheless, this is also suggestive of an
association between a higher expression haplotype of
BRCA2 in mutation carriers with lower risk of develop-
ing breast cancer.
Identification of regulatory variation
Next we aimed to dissect the genetic cis-regulation
responsible for the haplotype differences in the expres-
sion level of BRCA2. We performed a series of in silico,
in vitro (Figure 3) and in vivo (Figure 4) experiments in
human breast cells. Twenty-six SNPs tagged by all five
haplotypes were identified using Haploview and Hap-
Map data. We used four criteria for selecting SNPs for
further analyses. First, we selected the SNPs located
inside regulatory elements described by the Ensembl
database. Secondly, we selected the SNPs whose sur-
rounding DNA sequence was predicted to potentially
bind transcription factors (TF). For this purpose, 40 bps
of DNA sequence surrounding these SNPs were ana-
lyzed in silico using TRANSFAC and MATCH for deter-
mining likelihoods of these DNA sequences to bind TFs.
We used a cut-off of 0.9 for the matrix and core similar-
ity scores; these scores correspond to the quality of a
match between the DNA sequence and the TF binding
matrix and the core sequence of a matrix (the five most
conserved consecutive positions in a matrix), respec-
tively. Thirdly, the TF binding site needed to overlap the
SNP location. Finally, there had to be a difference
between alleles in terms of presence/absence of binding
and differences in scores between alleles.
The tag SNP specific for haplotype 2, rs1799943
(Functional SNP 1 in Figure 5), and another in complete
LD (rs9567552) were the only SNPs localized at the pro-
moter region of BRCA2. They map within a RNA poly-
merase II (PolII) binding site at the promoter region of
BRCA2. To confirm binding at the promoter site we
performed ChIP using RNA PolII-specific and
Table 2 rs4942440 genotype frequencies in BRCA2
mutation carriers by disease status and hazard-ratio
estimate
Unaffected (%) Affected (%) HR 95% CI P Value
GG 648 (70.36) 817 (73.47) 1
AG 246 (26.71) 271 (24.37) 0.84 (0.70, 1.01)
AA 27 (2.93) 24 (2.16) 0.76 (0.43, 1.36)
2-df test 0.13
Per allele 0.85 (0.72, 1.00) 0.048
CI, confidence interval; HR, hazard ratio.
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H3K79me2-specific antibodies (a histone modification
commonly associated with transcription elongation [42])
and verified occupancy at the site of these variants
(Additional file 8 Figure S2). In silico analysis (Addi-
tional file 9 Table S6) suggested that the DNA sequence
surrounding this polymorphism could bind OCT-1 with
both alleles and also C/EBPa, but only in the minor A
allele form. EMSAs showed that in vitro both alleles had
the ability to bind C/EBPa Figure 3A. Next, through
ChIP analysis using specific antibodies against OCT-1
and C/EBPa, we found the site to be occupied in vivo
by C/EBPa, in two breast cancer cell lines (Figure 4A).
The pull-down was significantly higher for C/EBPa in a
heterozygous cell line compared to another homozygous
for the G allele (Student’s t test P-value = 0.03). No
occupancy was verified for the rs9567552 site.
Three other SNPs passed our selection criteria for
analysis by EMSA to evaluate binding of the predicted
TFs in vitro, using nuclear protein extracts from two
breast cancer and one normal cell line. Two of these
three SNPs showed the ability to bind in vitro in an alle-
lic-preferential or allele-specific manner to the predicted
TFs (Figure 3B and 3C) and were further characterized
by ChIP analysis.
SNP rs9567576 (Functional SNP 2 in Figure 5), tag-
ging haplotypes 2 and 5, located in a regulatory feature
in intron 11, resides within a putative binding site for
the high-mobility group protein HMGA1, with the T
allele better matching the consensus sequence. The
band observed in the EMSA experiment (Figure 3B) was
consistently stronger for the T allele in replicate experi-
ments, corroborating the in silico predictions, although
the G allele could still bind. In a competition EMSA
experiment, an oligonucleotide centered on SNP
rs9567576 competed more efficiently for binding when
the SNP position was a T as compared to a G. Addi-
tionally, a consensus probe and a specific antibody
against HMGA1 competed strongly for binding. The
physical presence of HMGA1 at the rs9567576 site was
demonstrated by site-specific ChIP analysis in both
MCF-7 and MCF-10A cells (homozygous for the T allele
and heterozygous at rs9567576, respectively) (Figure 4B).
Although a stronger ChIP result was obtained for MCF-
10A cells (genotype TG), comparative sequencing of the
immunoprecipitate and the input chromatin, showed
that HMGA1 binds this site in the presence of both
alleles but there is a preferential binding for the T allele
(Figure 4B).
SNP rs4942485 (Functional SNP 3 in Figure 5), which
is tagged by rs4942440 and haplotype 4, maps inside a
regulatory feature in intron 20. It was predicted that the
A allele would bind the albumin D-binding protein
(DBP), while the G allele could bind the zinc finger pro-
tein 161 homolog (ZF5). EMSA experiments (Figure 3C)
showed strong binding for the labelled oligonucleotide
containing the A allele in the form of two bands. This
binding was more efficiently competed by the same
unlabelled oligonucleotide than the unlabelled probe
containing the G allele. Using consensus competition
probes and specific antibodies for DBP and antibodies
for two negative controls (OCT-1 and IgG), we con-
firmed that the top band corresponded to the binding
of DBP. For the G allele, EMSA studies suggested
potential binding of ZF5 in the form of a third lower
band when in the presence of Zn2+ in the binding buf-
fer. Competition was detected when using a specific
antibody against ZF5. However, stronger competition
Figure 3 In silico and in vitro DNA-protein binding studies.
EMSA results, binding sequence motifs for each transcription factor
and the DNA sequence around each SNP (alleles in red) are shown.
Sequences are shown in the strand direction for which the
prediction was found, and red underlines indicate homology
between TF motif and allele sequence. DNA motifs were obtained
from TRANSFAC and Schmidt et al. (C/EBPa) [12,50]. Arrows indicate
specific bands for each EMSA. (A) Both alleles of rs1799943 show
weak in vitro binding of C/EBPa. (B) Analysis of rs9567576, using cell
extract from two cell lines as indicated, and competition assays
indicate stronger binding of HMGA1 to the probe containing the T
allele. (C) EMSA analysis of rs4942485 for the A allele (upper panel)
and G allele (lower panel). The A allele shows strong binding to
DBP, as identified by competition assays. When using the probe
containing the G allele, a lower third band appears in the presence
of Zn2+ in the buffer, identified as binding to ZF5 in competition
assays. EMSA, electrophoretic mobility shift assay; DBP, d-binding
protein; SNP, single nucleotide polymorphism; TF, transcription
factors.
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was observed in the same experiment by an antibody
against DBP. These data suggest that DBP binding is
stronger to the A allele of the rs4942485 sequence, but
that possible binding can exist in the presence of the G
allele. Our chromatin immunoprecipitation experiments
in this region using specific antibodies support the in
vivo occupancy of this site by DBP in MCF-7 cells and
ZF5 in both MCF7 and MCF-10A cells (Figure 4C).
Due to the low frequency of this SNP, all cell lines
available for these studies were homozygous for the
common A allele, preventing us from establishing allele
preferences in vivo.
The list of the candidate SNPs for functional analysis
as well as information on the gene expression levels of
the transcription factors analyzed in this study, are pro-
vided as Additional files 10 and 11, respectively.
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Overall, we identified three SNPs linked to haplotypes
2, 4 and 5, which are located in previously described
regulatory elements, have the potential to alter the bind-
ing of TFs and are occupied in vivo in breast cancer and
normal cell lines (Figure 5). Although rs1799943 is the
tag for haplotype 2 and rs9567576 is a tag for haplo-
types 2 and 5, rs4942485 tags a subset of haplotype 4
(pairwise rs4942485 versus rs4942440 r2 = 0.55), which
suggests that further cis-variants might be acting on this
haplotype.
Discussion
The aim of our study was to investigate the effect of
regulatory genetic variation of the BRCA2 tumor sup-
pressor gene on disease risk. To this end, we identified
haplotypes associated with different expression levels of
BRCA2 in normal breast tissue (expression haplotypes)
and characterized three cis-acting polymorphisms that
alter the binding of transcription factors at regulatory
sites. We show that these expression haplotypes have an
impact on the expression profile of breast cells. Also, we
found some evidence of association between a high
expression haplotype and lower risk of developing breast
cancer among carriers of germline mutations in BRCA2.
The cells of individuals carrying inactivating germline
mutations in the BRCA2 gene rely on the expression of
BRCA2 from the remaining wild-type allele. There is
evidence that these cells have a different gene expression
profile and ability to repair double-strand DNA breaks
compared to cells carrying two wild-type alleles [21,22].
We have shown previously that BRCA2 shows differen-
tial allelic expression in normal breast tissue. These
observations raised the hypothesis that cis-regulatory
variation could modify the penetrance of germline
mutations in BRCA2, by varying the level of expression
of the remaining wild-type allele, if different levels of
haploinsufficiency are important. The functional effects
of haploinsufficiency at a given locus may vary from tis-
sue to tissue [22]. Many critical biological processes are
context specific and the overlap of cis-regulatory var-
iants across different tissues is predicted to be between
10% to 80% [43-45], suggesting that the expression hap-
lotypes can vary from tissue to tissue. It is therefore cri-
tical to study the relevant tissue when evaluating
mechanisms of effect on disease risk. The functional
data that we present were obtained from the study of
normal breast tissue from control individuals and breast
cell lines (normal and cancer).
Haplotypes associated with different levels of gene
expression were mapped in unrelated individuals, an
approach that has proven powerful to identify cis-acting
loci [46]. The difference of expression that we observed
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between the expression haplotypes is small, which sug-
gests that any effect in disease will also be subtle, as
expected for common variants. Further functional analy-
sis in breast cells revealed three cis-acting variants
affecting the binding of transcription factors which can
explain at least in part the differences in expression
level associated with the expression haplotypes. These
cis-acting variants were mapped to the promoter and
two intronic regulatory elements of BRCA2. The regula-
tory scenario suggested by our findings is complex, with
diverse regulatory variants playing a role in different
expression haplotypes. The catalogue of genetic varia-
tion is improving constantly through studies like the
1000 Genomes Project. The most recent data show
more than ten predicted haplotype blocks for the region
we studied here. We have analyzed a fraction of the
known variation and believe that there may be more cis-
variants regulating the expression of BRCA2 in breast
tissue, as in others.
In a recent report, Bellacosa and colleagues have
shown that BRCA2+/- heterozygous cells have an altered
gene expression profile compared with normal cells
from individuals without mutations and that this effect
is tissue-specific [22]. Even though the expression haplo-
types we identified are associated with small differences
in the expression of BRCA2 itself, our analyses revealed
that the gene expression level of some of the same
genes reported by Bellacosa et al. could be correlated
with the expression haplotypes. These genes were,
unsurprisingly, the ones with the most significant differ-
ences in the previous report. These findings suggest that
even subtle changes in the expression of BRCA2 can
have an impact on the phenotype of normal breast tis-
sue, which can be particularly important when only one
expressing allele is present.
In our association study we found some evidence
that the minor allele of SNP rs4942440 (corresponding
to a high expression haplotype) is associated with a
protective effect for the development of breast cancer
in mutation carriers. We hypothesize that the higher
the expression of BRCA2 from the remaining wild-type
allele the better the cells of a mutation carrier indivi-
dual will carry out DNA repair. The evidence of asso-
ciation in the present study is weak. Mutation phase
information for the samples used in the association
study was not available. As a consequence, the group
of BRCA2 mutation carriers who are heterozygous for
this SNP consists of a mixture of individuals who have
either the minor or the common allele on the wild
type haplotype. We are currently collecting detailed
pedigree information and will be able to use phase
information in the future, which will strengthen our
analysis. Genotyping of additional mutation carriers in
the future will further clarify the involvement of this
SNP in the penetrance of BRCA2 mutations in breast
cancer. The selection of SNPs for the disease associa-
tion analysis, as well as the gene expression studies,
was performed based on our previous data associating
these SNPs/haplotypes with different levels of BRCA2
expression. It is difficult therefore to apply an exact
multiple testing, but taken together, the gene expres-
sion and association results are suggestive for the
involvement of this SNP in breast cancer risk for
BRCA2 mutation carriers.
Conclusions
Our findings support that quite subtle levels of haploin-
sufficiency of a tumor suppressor gene can have biologi-
cally relevant effects. Others have reported similar
effects for mutations in the PTEN and TP53 genes in
mouse models and APC in Familial Adenomatous Poly-
posis in humans [47-49]. Common regulatory variation
affecting the expression of APC and TGFBR1 has also
been shown to contribute to susceptibility to cancer in
humans [3,4]. Furthermore, common variants of the
BRCA1 wild-type allele have also been recently sug-
gested to modify the risk of breast cancer in BRCA1
mutations carriers [50]. In the future, a confirmation of
these findings could be performed by direct measure-
ment of BRCA2 expression levels in mutation carriers
and even BRCA2 protein levels. The functional interac-
tions between genetic variability, transcriptional regula-
tion and cancer susceptibility are largely unexplored.
Our findings highlight the importance of investigating
the regulatory genetic variation of tumour suppressor
genes in the search for genetic modifiers of mutation
penetrance.
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